Antibodies, Complement, and a Durable Therapeutic Response in Oncology

• Antibodies can initiate tumor rejection
• Intra-tumoral complement activation alters the local tumor microenvironment
• Anti-tumor immunity drives a long-term clinical response

Speakers:

Edward Patz

Chief Executive Officer

Grid Therapeutics